RGV004
/ Hangzhou Rongu Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 06, 2023
Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma
(clinicaltrials.gov)
- P1 | N=25 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting ➔ Recruiting
Enrollment open • Oncolytic virus • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19
1 to 1
Of
1
Go to page
1